Contracting in Medical Equipment Maintenance Services: An Empirical Investigation

Patent-based measures are frequently used as indicators in empirical research on innovation and technological change. Currently, there is little evidence as to what extent patent-based indicators relate to product market outcomes. Using a unique dataset that links outcomes from product commercialization in the pharmaceutical industry with detailed patent data, we relate patent-based indicators that capture either an invention's value or the uncertainty surrounding the patenting process to the outcomes of the product development process. Our findings suggest that the speed of commercialization increases with value but reduces with uncertainty. Using a variety of alternative indicators we derive implications for the use and the proper interpretation of individual measures. Moreover, our study has broader implications as it highlights the detrimental effect of uncertainty on the speed of innovation.

[1]  Dietmar Harhoff,et al.  Recent Research on the Economics of Patents , 2012 .

[2]  Christian Sternitzke,et al.  Knowledge sources, patent protection, and commercialization of pharmaceutical innovations☆ , 2010 .

[3]  Toby E. Stuart.  Network Positions and Propensities to Collaborate: An Investigation of Strategic Alliance Formation in a High-Technology Industry , 1998 .

[4]  Jean O. Lanjouw,et al.  How to Count Patents and Value Intellectual Property: Uses of Patent Renewal and Application Data , 1996 .

[5]  Stefan Wagner,et al.  Patents and the Survival of Internet-Related Ipos , 2007 .

[6]  James E. Bessen,et al.  Estimates of Patent Rents from Firm Market Value , 2007 .

[7]  M. Gittelman,et al.  A Note on the Value of Patents as Indicators of Innovation: Implications for Management Research , 2008 .

[8]  Mark A. Schankerman,et al.  Patent Quality and Research Productivity: Measuring Innovation with Multiple Indicators , 2004 .

[9]  M. Trajtenberg,et al.  University Versus Corporate Patents: A Window On The Basicness Of Invention , 1997 .

[10]  M. Trajtenberg.  A Penny for Your Quotes : Patent Citations and the Value of Innovations , 1990 .

[11]  Michelle Gittelman.  Comment: The value of European patents , 2008 .

[12]  Franco Malerba,et al.  Technological entry, exit and survival: an empirical analysis of patent data , 1999 .

[13]  Toby E. Stuart,et al.  Syndication Networks and the Spatial Distribution of Venture Capital Investments1 , 1999, American Journal of Sociology.

[14]  Iain M. Cockburn,et al.  Entry and Patenting in the Software Industry , 2006, Manag. Sci..

[15]  Dominique Guellec,et al.  Claiming More: The Increased Voluminosity of Patent Applications and its Determinants , 2006 .

[16]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[17]  Ufuk Akcigit,et al.  Patent Value and Citations: Creative Destruction or Strategic Disruption? , 2013 .

[18]  N. Kiefer.  Economic Duration Data and Hazard Functions , 1988 .

[19]  Ariel Pakes,et al.  Estimates of the Value of Patent Rights in European Countries During Thepost-1950 Period , 1985 .

[20]  P. Thompson,et al.  Patent Citations and the Geography of Knowledge Spillovers: A Reassessment , 2005 .

[21]  Dietmar Harhoff,et al.  How to measure patent thickets—A novel approach , 2011 .

[22]  Mario Cleves,et al.  An Introduction To Survival Analysis Using Stata Third | , 2012 .

[23]  M. Trajtenberg,et al.  Universities as a Source of Commercial Technology: A Detailed Analysis of University Patenting, 19651988 , 1995, Review of Economics and Statistics.

[24]  D. Harhoff,et al.  The Value of European Patents , 2008 .

[25]  Mark A. Schankerman,et al.  Characteristics of patent litigation: a window on competition , 2001 .

[26]  Kimberly S. Hamilton,et al.  The increasing linkage between U.S. technology and public science , 1997 .

[27]  Scott Shane,et al.  When do start-ups that exploit patented academic knowledge survive? , 2003 .

[28]  A. Pakes,et al.  The Rate of Obsolescence of Knowledge, Research Gestation Lags, and the Private Rate of Return to Research Resources , 1979 .

[29]  Colin Webb,et al.  Analysing European and International Patent Citations , 2005 .

[30]  D. Mowery,et al.  Strategic alliances and interfirm knowledge transfer , 1996 .

[31]  Francis Narin,et al.  Is technology becoming science? , 1985, Scientometrics.

[32]  Z. Griliches.  Patent Statistics as Economic Indicators: a Survey , 1990 .

[33]  Georg von Graevenitz,et al.  Incidence and Growth of Patent Thickets: The Impact of Technological Opportunities and Complexity , 2008 .

[34]  Jacques Michel,et al.  Patent citation analysis.A closer look at the basic input data from patent search reports , 2001, Scientometrics.

[35]  Christian Sternitzke,et al.  An exploratory analysis of patent fencing in pharmaceuticals: The case of PDE5 inhibitors , 2013 .

[36]  Bruno van Pottelsberghe de la Potterie,et al.  A brief history of space and time: The scope-year index as a patent value indicator based on families and renewals , 2008, Scientometrics.

[37]  Martin Meyer,et al.  Patent Citations in a Novel Field of Technology — What Can They Tell about Interactions between Emerging Communities of Science and Technology? , 2000, Scientometrics.

[38]  Katharine Rockett,et al.  Innovation Cycles and Learning at the Patent Office: Does the Early Patent Get the Delay? , 2010 .

[39]  Dietmar Harhoff,et al.  Modelling the Duration of Patent Examination at the European Patent Office , 2005, Manag. Sci..

[40]  Heidi L. Williams,et al.  Intellectual Property Rights and Innovation: Evidence from the Human Genome , 2013, Journal of Political Economy.

[41]  Petra Moser,et al.  Patent Citations - An Analysis of Quality Differences and Citing Practices in Hybrid Corn , 2016 .

[42]  Yulia V. Marchenko,et al.  An Introduction to Survival Analysis Using Stata, Third Edition , 2010 .

[43]  D. Cox.  Regression Models and Life-Tables , 1972 .

[44]  Gilbert MacKenzie,et al.  The Statistical Analysis of Failure Time Data , 1982 .

[45]  Z. Griliches,et al.  Citations, Family Size, Opposition and the Value of Patent Rights Have Profited from Comments and Suggestions , 2002 .

[46]  A. Jaffe.  Technological Opportunity and Spillovers of R&D: Evidence from Firms&Apos; Patents, Profits and Market Value , 1986 .

[47]  D. Harhoff,et al.  Determinants of Opposition against EPO Patent Grants – The Case of Biotechnology and Pharmaceuticals ∗ , 2002 .

[48]  D. Harhoff,et al.  Citation Frequency and the Value of Patented Inventions , 1999, Review of Economics and Statistics.

[49]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[50]  Rosemarie H. Ziedonis.  Don't Fence Me in: Fragmented Markets for Technology and the Patent Acquisition Strategies of Firms , 2003, Manag. Sci..

[51]  Bhaven N. Sampat,et al.  Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals , 2011, Journal of health economics.

[52]  Bronwyn H Hall,et al.  Market value and patent citations , 2005 .

[53]  Megan J. MacGarvie,et al.  Patents, Thickets and the Financing of Early-Stage Firms: Evidence from the Software Industry , 2007 .

[54]  Dietmar Harhoff,et al.  Corporate Social Responsibility, Multi-faceted Job-Products, and Employee Outcomes , 2013, Journal of Business Ethics.

[55]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[56]  Van V. Brantner,et al.  Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.